Biologic aspects of expression of stably integrated transgenes in cells of the skin in vitro and in vivo

Proceedings of the Association of American Physicians

Volumn 111, Issue 3, 1999, Pages 198-205

  Krueger, G G ^a   Morgan, J R ^a   Petersen, M J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Athymic mice; Gene therapy; Human fibroblasts; Immortalized fibroblasts; Nylon matrix; Retroviral vectors

Indexed keywords

CELL IMMORTALIZATION; CELL SURVIVAL; EPIDERMIS; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; KERATINOCYTE; NORMAL HUMAN; REVIEW; SIGNAL TRANSDUCTION; SKIN CELL; TRANSGENE;

EID: 0033047360     PISSN: 1081650X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1381.1999.99225.x     Document Type: Review

References (48)

1. 1 Krueger G.G. & Pershing L.K.: Skin xenografts and their utility in pharmacologic research. In: Pharmacology of the Skin. Mukhtar H. (ed.). Boca Raton: CRC Press, 41 72, 1992.
2. 2 Khavari P & Krueger G.: Cutaneous gene therapy. In: Dermatologic Clinics. Theirs B.H. (ed.). Philadelphia: W.B. Saunders, 27 33, 1997.
3. 3 Krueger G., Morgan J., Jorgensen C., et al. Genetically modified skin to treat disease: potential and limitations. J. Invest Dermatol. 103: 76S 84S, 1994.
4. 4 Friedmann T. Human gene therapy—an immature genie, but certainly out of the bottle. Nature Med. 2: 144 147, 1996.
5. 5 Leiden J.M. Gene therapy—promise, pitfalls, and prognosis. New Engl. J. Med. 333: 871 873, 1995.
6. 6 Marshall E. Gene therapy’s growing pains. Science 269: 1050 1055, 1995.
7. 7 Blau H. & Khavari P. Gene therapy: Progress, problems, prospects. Nat Med. 3: 612 613, 1997.
8. 8 Heartlein M.W., Roman V.A., Jiang J.L., et al. Long‐term production and delivery of human growth hormone in vivo. Proc. Natl. Acad. Sci. U.S.A. 91: 10967 10971, 1994.
9. 9 Palmer T.D., Rosman G.J., Osborne W.R.A., Miller A.D. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. U.S.A. 88: 1330 1334, 1991.
10. 10 Krueger G.G., Jorgensen C.M., Petersen M.J., et al. Use of cloned genetically modified human fibroblasts to assess long‐term survival in vivo. Hum. Gene Ther. 8: 523 532, 1997.
11. 11 Chen B.F., Chang W.C., Chen S.T., et al. Long‐term expression of the biologically active growth hormone in genetically modified fibroblasts after implantation into a hypophysectomized rat. Hum. Gene Ther. 6: 917 926, 1995.
12. 12 Chang P.L., Shen N., Westcott A.J. Delivery of recombinant gene products with microencapsulated cells in vivo. Hum. Gene Ther. 4: 433 440, 1993.
13. 13 Dwarki V.J., Belloni P., Nijjar T., et al. Gene therapy for hemophilia A. Production of therapeutic levels of human factor VIII in vivo in mice. Proc. Natl. Acad. Sci. U.S.A. 92: 1023 1027, 1995.
14. 14 Garver R.I., Chytil A., Courtney M., Crysral R.G. Clonal gene therapy: transplanted mouse fibroblast clones express alpha 1‐trypsin gene in vivo. Science 237: 714 718, 1987.
15. 15 Gilbert J.C., Takada T., Stein J.E., et al. Cell transplantation of genetically altered cells on biodegradable polymer scaffolds in syngeneic rats. Transplantation 56: 423 427, 1993.
16. 16 Hoeben R.C., Migchielsen A.A., Van Der Jagt R.C., et al. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J. Virol. 65: 904 912, 1991.
17. 17 Moullier P., Bohl D., Heard J., Danos O. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat. Genet. 4: 154 159, 1993.
18. 18 Naffakh N., Henri A., Villeval J.L., et al. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92: 3194 3198, 1995.
19. 19 Ogura H., Tani K., Ozawa K., et al. Implantation of genetically manipulated fibroblasts into mice as antitumor a‐interferon therapy. Cancer Res. 50: 5102 5106, 1990.
20. 20 Ramesh N., Lau S., Palmer T.D., et al. High‐level human adenosine deaminase expression in dog skin fibroblasts is not sustained following transplantation. Hum. Gene Ther. 4: 3 7, 1993.
21. 21 Scharfmann R., Axelrod J.H., Verma I.M. Long‐term in vivo expression of retrovirus‐mediated gene transfer in mouse fibroblast implants. Proc. Natl. Acad. Sci. U.S.A. 88: 4626 4630, 1991.
22. 22 Selden R.F., Skoskiewicz M.J., Howie K.B., Russell P.S., Goodman H.M. Implantation of genetically engineered fibroblasts into mice: implications for gene therapy. Science 236: 714 718, 1987.
23. 23 St. Louis D. and Verma I.M. An alternative approach to somatic cell gene therapy. Proc. Natl. Acad. Sci. U.S.A. 85: 3150 3154, 1988.
24. 24 Elder E.M., Lotze M.T., Whiteside T.L. Successful culture and selection of cytokine gene‐modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum. Gene Ther. 7: 479 487, 1996.
25. 25 Hoeben R.C., Fallaux F.J., Van Tilburg N.H., et al. Toward gene therapy for hemophilia A. Long‐term persistence of factor VIII‐secreting fibroblasts after transplantation into immunodeficient mice. Hum. Gene Ther. 4: 179 186, 1993.
26. 26 Petersen J.M., Kaplan J., Jorgensen M.C., et al. Sustained production of human transferrin by transduced fibroblasts implanted into athymic mice: a model for somatic gene therapy. J. Invest Dermatol. 104: 171 176, 1995.
27. 27 Naughton G.K., Jacob L., Naughton B.A.: A physiological skin model for ‘in vitro’ toxicity studies. In: Alternative Methods in Toxicology. Goldberg A.M. and Principle M.L. (eds.). New York: MaryAnn Leibert Inc., 183 189, 1989.
28. 28 Fleischmajer R., MacDonald E., Contard P., Perlish J. Immunohistochemistry of a keratinoctye‐fibroblast co‐culture model for reconstruction of human skin. J. Histochem. Cytochem. 41: 1359 1366, 1993.
29. 29 Krueger G., Liimatta A., Jorgensen C., Morgan J. Prolongation of genetically modified human fibroblasts in culture in an extracellular nylon matrix enhances survival in vivo. J. Invest Dermatol. 106: 806A, 1996.
30. 30 Krueger G.G., Jorgensen C.M., Morgan J.R., et al. Loss of transgene expression in vivo can be slowed, but not eliminated, by sequestering cells. J. Invest Dermatol. 110: 609, 1998.
31. 31 Halbert C., Demers G., Galloway D. The E7 gene of human papilloma virus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65: 473 478, 1991.
32. 32 Jorgensen C., Matsunami N., Morgan J., et al. Immortalized human keratinocytes form a functional epidermis and express transgenes in vivo. J. Invest Dermatol. 108: 595A, 1997.
33. 33 Krueger G.G., Matsunami N., Jorgensen C.M., et al. Differentiation of immortalized human keratinocytes in vivo. J. Invest Dermatol. 110: 608, 1998.
34. 34 Choate K.A. & Khavari P.A. Sustainability of keratinocyte gene transfer and cell survival in vivo. Hum. Gene Ther. 8: 895 901, 1997.
35. 35 Choate K.A. & Khavari P.A. Direct cutaneous gene delivery in a human genetic skin disease. Hum. Gene Ther. 8: 1659 1665, 1997.
36. 36 Fenjves E.S., Yao S.N., Kurachi K., Taichman L.B. Loss of expression of a retrovirus‐transduced gene in human keratinocytes. J. Invest Dermatol. 106: 576 578, 1996.
37. 37 Fenjves E.S., Schwartz P.M., Blaese R.M., Taichman L.B. Keratinocyte gene therapy for adenosine deaminase deficiency: A model approach for inherited metabolic disorders. Hum. Gene Ther. 8: 911 917, 1997.
38. 38 Gerrard A.J., Hudson D.L., Brownlee G.G., Watt F.M. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat. Genet. 3: 180 183, 1993.
39. 39 Jensen U.B., Jensen T.G., Jensen P.K., et al. Gene transfer into cultured human epidermis and its transplantation onto immunodeficient mice: an experimental model for somatic gene therapy. J. Invest. Dermatol. 103: 391 394, 1994.
40. 40 Stockschlader M.A., Schuening F.G., Graham T.C., Storb R. Transplantation of retrovirus‐transduced canine keratinocytes expressing the beta‐galactosidase gene. Gene-Ther 1: 317 322, 1994.
41. 41 Bodnar A., Ouellette M., Frolkis M., et al. Extension of life‐span by introduction of telomerase into normal human cells. Science 279: 349 352, 1998.
42. 42 Merlo G.R., Cella N., Hynes N.E. Apoptosis is accompanied by changes in Bcl‐2 and Bax expression, induced by loss of attachment, and inhibited by specific extracellular matrix proteins in mammary epithelial cells. Cell Growth Differ 8: 251 260, 1997.
43. 43 Boudreau N., Werb Z., Bissell M. Suppression of apoptosis by basement membrane requires three‐dimensional tissue organization and withdrawal from the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 93: 3509 3513, 1996.
44. 44 Gailit J. & Clark R.A. Studies in vitro on the role of alpha v and beta 1 integrins in the adhesion of human dermal fibroblasts to provisional matrix proteins fibronectin, vitronectin, and fibrinogen. J. Invest. Dermatol. 106: 102 108, 1996.
45. 45 Weaver V.M., Fischer A.H., Peterson O.W., Bissell M.J. The importance of the microenvironment in breast cancer progression: Recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three‐dimensional culture assay. Biochem. Cell Biol. 74: 833 851, 1996.
46. 46 Demers G.W., Espling E., Harry J.B., et al. Abrogation of growth arrest signals by human papillomavirus type 16, E7 is mediated by sequences required for transformation. J. Virol. 70: 6862 6869, 1996.
47. 47 Ghazizadeh S., Carroll J.M., Taichman L.B. Repression of retrovirus‐mediated transgene expression by interferons: Implications for gene therapy. J. Virol. 71: 9163 9169, 1997.
48. 48 Eming S.A., Medalie D.A., Tompkins R.G., et al. Genetically modified human keratinocytes overexpressing PDGF‐A enhance the performance of a composite skin graft. Hum. Gene Ther. 9: 529 539, 1998.